Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexlansoprazole MR vs Lansoprazole in Erosive Esophagitis
NCT00251693Phase 3Completed
- Sponsor
- Takeda
- Start
- Dec 2005
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of dexlansoprazole in erosive esophagitis (EE) (3 arms), sponsored by Takeda. Primary endpoints: Percentage of Subjects With Complete Healing of Erosive Esophagitis (EE) by Week 8 as Assessed by Endoscopy - Crude Rate Analysis and Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method. Started Dec 2005; status: completed.
02
Drugs
dexlansoprazole
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on NCT00251693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251693.